Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Concord
Clinical trial register · Australia

Clinical Trials in Concord, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Australia and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 3343 matching records held by the registry are in this view. Synced 15 Oct 2026, 03:18 UTC
3343
Studies in scope
all four open statuses
1804
Recruiting now
open to new participants
765
Lead sponsors
across recruiting studies
Top sites
Melbourne 1096 Adelaide 565 Sydney 508 Westmead 416 Clayton 407
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
BeOne Medicines13 Janssen Research & Development, LLC10 Boehringer Ingelheim7 AstraZeneca6 AbbVie5
Site location
Melbourne1096 Adelaide565 Sydney508 Westmead416 Clayton407
All 401 locations
Target enrolment
to

Trials with a site in Concord

124 of 3343 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Australia
Start
Recruiting
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Concord, North Ryde, Woodville South, Clayton, Epping, Frankston
2026-09
Recruiting
Soufflé Therapeutics, Inc.
Phase 1/2
90
Concord, Liverpool, Brisbane, South Brisbane, Melbourne
2026-09
Recruiting
Janssen Research & Development, LLC
Phase 2
230
Concord, Wollongong
2026-06-30
Recruiting
AstraZeneca
Phase 3
750
Concord, Darlinghurst, East Melbourne, Fitzroy, Liverpool, Melbourne, Murdoch, Waratah
2026-06-26
Recruiting
BeOne Medicines
Phase 1
118
Concord, Kogarah, Kurralta Park, Geelong, Heidelberg, Nedlands
2026-06-23
By invitation
Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD
NCT07652294Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Concord, South Brisbane
2026-06-08
Recruiting
Jade Biosciences, Inc.
Phase 2
30
Concord, Liverpool, Parkville
2026-05-19
Recruiting
Incyte Corporation
Phase 1
218
Concord, St Leonards, Auchenflower, East Melbourne, Nedlands
2026-05-11
Recruiting
Boehringer Ingelheim
Phase 2
132
Concord, Kingswood, New Lambton Heights, Brisbane, Woolloongabba
2026-03-23
Recruiting
Nura Bio
Phase 1/2
80
Concord, Randwick, Brisbane, Bedford Park, Caulfield South, Nedlands
2026-03-04
Recruiting
Boehringer Ingelheim
Phase 3
286
Concord, Kingswood, Kogarah, Westmead, Herston, Southport, Adelaide, AT Albans
2026-02-16
Recruiting
BeOne Medicines
Phase 3
500
Blacktown, Concord, St Leonards, Woolloongabba, Clayton, Heidelberg, Malvern, Melbourne
2026-01-22
Recruiting
Incyte Corporation
Phase 2
160
Blacktown, Concord, Adelaide, Hobart
2025-11-12
Recruiting
Janssen Research & Development, LLC
Phase 2/3
1,092
Clayton, Concord, Fitzroy, Murdoch, New Lambton Heights, South Brisbane
2025-10-03
Recruiting
Janssen Research & Development, LLC
Phase 3
882
Clayton, Concord, Fitzroy, Murdoch, New Lambton Heights, Parkville, South Brisbane
2025-10-01
Recruiting
Vertex Pharmaceuticals Incorporated
Phase 2/3
176
Clayton, Concord, Kogarah, New Lambton Heights
2025-09-30
Recruiting
Alnylam Pharmaceuticals
Phase 3
11,000
Auchenflower, Brisbane, Brookvale, Castle Hill, Clayton, Concord, Douglas, Gosford
2025-09-22
Recruiting
BeOne Medicines
Phase 3
500
Concord, Kogarah, Westmead, Benowa, Birtinya, Tugun, Bedford PK, Fitzroy
2025-09-04
Recruiting
Amgen
Phase 3
11,000
Garran, Camperdown, Charlestown, Concord, Merewether, Orange, Wollongong, Auchenflower
2025-08-22
Recruiting
Takeda
Phase 3
150
Garran, Concord, Kogarah, Liverpool, Westmead, Melbourne, Murdoch, West Perth
2025-08-14
Recruiting
Boehringer Ingelheim
Phase 3
11,800
Garran, Blactown, Burwood, Camperdown, Concord, Liverpool, New Lambton Heights, St Leonards
2025-07-22
Recruiting
Novo Nordisk A/S
Phase 2
200
Concord, Brisbane, Adelaide, Bedford Park, Hobart, Clayton, Murdoch
2025-06-30
Recruiting
A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
NCT07012395Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis, Colitis, Ulcerative
DrugsSPY001·SPY002·SPY003
Spyre Therapeutics, Inc.
Phase 2
645
Murdoch, Concord, Heidelberg, Liverpool, Melbourne, South Brisbane, Woolloongabba
2025-05-27
Recruiting
Biogen
Phase 3
180
Concord, Kogarah, Liverpool, Westmead, Douglas, Herston, Southport, Clayton
2025-05-22
Recruiting
BeOne Medicines
Phase 3
250
Concord, Gosford, Port Macquarie, Randwick, Toowoomba, Bedford PK, Melbourne, West Perth
2025-04-10
Recruiting
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
NCT06714006Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PYC Therapeutics
Phase 1
166
Southport, Concord, Liverpool, Randwick, Wahroonga, Westmead, South Brisbane, Fitzroy
2025-04-07
Active, closed
Janssen Research & Development, LLC
Phase 1
85
Concord, Melbourne, Nedlands
2025-03-21
Recruiting
Bayer
Phase 1/2
450
Camperdown, Concord, Epping, Waratah
2025-03-21
Recruiting
Takeda
Phase 3
171
Garran, Concord, Kogarah, Liverpool, Westmead, Melbourne, Murdoch, West Perth
2025-02-27
Active, closed
Stemline Therapeutics, Inc.
Phase 2
85
Concord, Douglas, Adelaide, Box Hill, Clayton, Fitzroy, Heidelberg, Perth
2025-01-14
Recruiting
Janssen Research & Development, LLC
Phase 3
700
Concord, Heidelberg, South Woodville, St Albans
2024-12-12
Active, closed
Vicore Pharma AB
Phase 2
378
Footscray, Adelaide, Brisbane, Concord, Darlinghurst, Douglas, Heidelberg, Sydney
2024-12-09
Recruiting
Shanghai Henlius Biotech
Phase 3
550
Fitzroy, Frankston, Sunshine Coast, Campbelltown, Gosford, North Ryde, Concord
2024-11-22
Active, closed
Daiichi Sankyo
Phase 3
700
Adelaide, Bedford Park, Box Hill, Concord, Darlinghurst, Douglas, Liverpool, Melbourne
2024-11-19
Recruiting
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
NCT06637332Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, S. Aureus Bacteremia, S. Aureus Bloodstream Infection
DrugsDaptomycin·Vancomycin
Todd C. Lee MD MPH FIDSA
Phase 4
300
Blacktown, Concord, Newcastle, Westmead, Herston, Bedford Park, Berwick, Box Hill
2024-11-14
Recruiting
GigaGen, Inc.
Phase 1
48
Concord, Fortitude Valley
2024-11-13
Recruiting
Boehringer Ingelheim
Phase 3
1,590
Concord, Kingswood, Liverpool, Westmead, Clayton, Heidelberg, Parkville, Perth
2024-11-12
Active, closed
Janssen Research & Development, LLC
Phase 1
19
Concord, Fitzroy, North Ryde
2024-10-22
Recruiting
Boehringer Ingelheim
Phase 3
1,800
Concord, Kingswood, Liverpool, Westmead, Birtinya, Clayton, Heidelberg, Parkville
2024-10-14
Active, closed
Boehringer Ingelheim
Phase 3
8,371
Concord, Gosford, Kingswood, Kogarah, Liverpool, Port Macquarie, Pialba, Southport
2024-08-30
Active, closed
Alpine Immune Sciences Inc, A Subsidiary of Vertex
Phase 3
605
Ballarat, Bendigo, Birtinya, Brisbane, Camperdown, Clayton, Concord, Garran
2024-08-30
Recruiting
Bayer
Phase 3
555
Blacktown, Concord, Waratah, Buderim, Toowoomba, Heidelberg
2024-08-28
Recruiting
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
NCT06351592Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Regeneron Pharmaceuticals
Phase 1/2
54
Concord, Sydney, Birtinya
2024-08-28
Recruiting
AstraZeneca
Phase 3
620
Chermside, Clayton, Concord, Nedlands
2024-08-12
Recruiting
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
NCT06257706Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
DrugVedolizumab
Alimentiv Inc.
Phase 4
304
Concord, South Brisbane, Adelaide, Woodville, Epping, Heidelberg, Melbourne, Murdoch
2024-08-07
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
DrugsIptacopan·Rituximab
Novartis Pharmaceuticals
Phase 2
84
Concord, Clayton
2024-08-05
Recruiting
Vor Biopharma
Phase 3
180
Concord, Douglas, Southport
2024-07-17
Active, closed
Novo Nordisk A/S
Phase 3
10,000
Concord, Kingswood, Liverpool, Randwick, Wollongong, Birtinya, Brisbane, Cairns
2024-06-25
Recruiting
Boehringer Ingelheim
Phase 3
6,712
Garran, Concord, Gosford, Kingswood, Kotara, Brisbane, Chermside, Tugun
2024-06-17
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,200
Concord, Brisbane, Adelaide, Clayton, Melbourne
2024-06-05
Recruiting
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
NCT06237452Clostridium Difficile, Clostridium Difficile Infections, Clostridium Difficile Infection Recurrence, Clostridioides Difficile Infection
Vedanta Biosciences, Inc.
Phase 3
852
Concord, Westmead, Clayton, Parkville
2024-05-20
Active, closed
Janssen-Cilag Ltd.
Phase 3
120
Adelaide, Concord, Melbourne, Murdoch, South Brisbane
2024-04-17
Recruiting
AstraZeneca
Phase 3
3,850
Blacktown, Cairns, Canberra, Chermside, Clayton, Concord, Frankston, Geelong
2024-04-12
Active, closed
Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)
NCT06291376Immunoglobulin A Nephropathy, IgAN
DrugRavulizumab
Alexion Pharmaceuticals, Inc.
Phase 3
584
Canberra, Clayton, Concord, Herston, Liverpool, Perth, Southport, St Albans
2024-03-29
Recruiting
Takeda
Phase 2
268
Concord, South Brisbane, Bedford Park, Woodville, Footscray, Murdoch, Perth, Epping
2024-03-05
Recruiting
Pfizer
Phase 3
492
Blacktown, Concord, Birtinya, Brisbane, Fitzroy, Geelong, Nedlands
2024-02-08
Recruiting
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT06120283Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer
DrugsBGB-43395·Elacestrant·Letrozole·Fulvestrant
BeOne Medicines
Phase 1
433
Blacktown, Bowral, Concord, North Ryde, Douglas, Adelaide, Heidelberg, Melbourne
2023-12-01
Recruiting
Amgen
Phase 3
750
Campbelltown, Concord, Kingswood, Port Macquarie, St Leonards, Waratah, Toowoomba, Woolloongabba
2023-11-16
Active, closed
BeOne Medicines
Phase 3
652
Concord, St Leonards, Benowa, Birtinya, Woolloongabba, Bedford PK, Clayton, Fitzroy
2023-11-11
Recruiting
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
NCT05862012Relapsed/Refractory Multiple Myeloma
Ichnos Sciences SA
Phase 1
200
Concord, Benowa, Fitzroy, Melbourne, Nedlands
2023-11-01
Recruiting
LeonaBio
Phase 3
600
Blacktown, Concord, South Brisbane
2023-10-31
Active, closed
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
NCT05952037Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent, Waldenstrom's Macroglobulinemia Refractory
DrugsSonrotoclax·Zanubrutinib
BeOne Medicines
Phase 2
114
Concord, St Leonards, Woolloongabba, Bedford PK, Clayton, Fitzroy, Nedlands, Perth
2023-10-23
Active, closed
Seagen, a wholly owned subsidiary of Pfizer
Phase 3
412
Concord, Darlinghurst, Macquarie University, North Ryde, Randwick, Brisbane, Chermside, Herston
2023-09-22
Active, closed
Hoffmann-La Roche
Phase 3
1,130
Concord, Randwick, Douglas, Woolloongabba, Bedford Park, Hobart, Box Hill, Fitzroy
2023-09-18
Recruiting
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.
Phase 1
165
Concord, Sydney, Westmead, Frankston, Melbourne, Nedlands
2023-09-14
Recruiting
DualityBio Inc.
Phase 1/2
862
Blacktown, Camperdown, Concord, New Lambton Heights, Sydney, Waratah, Birtinya, Brisbane
2023-08-17
Active, closed
AbbVie
Phase 3
1,014
Botany, Concord, Darlinghurst, Tiwi, Woodville, Camberwell, Clayton, Victoria Park
2023-07-25
Recruiting
Kirby Institute
Phase 3
320
Blacktown, Camperdown, Concord, Darlinghurst, Westmead
2023-07-21
Recruiting
Hoffmann-La Roche
Phase 1/2
320
Concord, Melbourne
2023-06-20
Recruiting
Hoffmann-La Roche
Phase 3
420
Campbelltown, Coffs Harbour, Concord, Darlinghurst, Gosford, Auchenflower, Sippy Downs, Bendigo
2023-06-07
Active, closed
AbbVie
Phase 1
39
Concord, Fitzroy Melbourne, Nedlands
2023-04-26
Active, closed
Janssen Research & Development, LLC
Phase 3
20,284
Adelaide, Brisbane, Concord, Frankston, Garran, Herston, Joondalup, Kotara
2023-04-11
Recruiting
AstraZeneca
Phase 3
4,300
Birtinya, Concord, Nedlands, Randwick, Tweed Heads, Waratah, Wendouree
2023-03-31
Active, closed
An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases
NCT05732402Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
DrugPovetacicept
Alpine Immune Sciences, Inc.
Phase 1/2
72
Concord, Saint Albans, Nedlands
2023-03-15
Active, closed
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383Primary Prevention of Atherosclerotic Cardiovascular Disease
DrugInclisiran
Novartis Pharmaceuticals
Phase 3
14,012
Garran, Camperdown, Concord, Auchenflower, Sippy Downs, Woolloongabba, Adelaide, Leabrook
2023-03-09
Active, closed
ABTECT - Maintenance
NCT05535946Ulcerative Colitis
DrugObefazimod
Abivax S.A.
Phase 3
1,116
Concord, Fitzroy, Melbourne, Parkville
2023-01-16
Active, closed
Amgen
Phase 3
7,297
Garran, Camperdown, Concord, Liverpool, Sydney, Wollongong, Auchenflower, Bundaberg
2022-12-14
Active, closed
Dizal Pharmaceuticals
Phase 3
324
Concord, Melbourne, Nedlands, Randwick
2022-12-13
Recruiting
Monash University
Phase 2/3
300
Garran, Concord, St Leonards, Clayton, Heidelberg, Melbourne, St Albans
2022-11-30
Active, closed
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
NCT05611671Inflammatory Bowel Diseases, Colitis, Ulcerative
DrugZotemtegrast
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase 2
280
Blacktown, Concord, Herston, Murdoch, South Brisbane
2022-11-21
Recruiting
Canadian Cancer Trials Group
Phase 2
84
Concord, Nowra, Wollongong, Adelaide, Heidelberg, Perth
2022-11-01
Active, closed
Janssen Research & Development, LLC
Phase 2
577
Box Hill, Camperdown, Clayton, Concord, Footscray, Maroochydore, Murdoch, North Terrace
2022-09-19
Recruiting
The University of Queensland
Not applicable
372
Concord, Frenchs Forest, Kogarah, Liverpool, New Lambton Heights, Port Macquarie, Saint Leonards, Bundaberg
2022-07-06
Active, closed
Bausch Health Americas, Inc.
Phase 3
524
Concord, Kingswood, Bedford Park, Box Hill, Parkville, Murdoch, Perth
2022-04-07
By invitation
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 2/3
600
Garran, Concord, Kogarah, New Lambton Heights, Saint Leonards, Adelaide, Fitzroy, St Albans
2022-04-05
Active, closed
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
530
Garran, Concord, Kogarah, Liverpool, New Lambton Heights, Randwick, Saint Leonards, Adelaide
2022-03-15
Active, closed
BeOne Medicines
Phase 3
799
Concord, Gosford, Kogarah, Orange, Port Macquarie, Westmead, Douglas, North Adelaide
2022-03-10
Recruiting
University of Melbourne
Phase 4
8,000
Garran, Blacktown, Camperdown, Concord, Darlinghurst, Kingswood, Kogarah, Liverpool
2022-02-16
Recruiting
Concord Repatriation General Hospital
Not applicable
476
Camperdown, Concord, Gosford, Randwick, Westmead, Brisbane, Fitzroy, Heidelberg
2022-01
Recruiting
Takeda
Phase 2
135
Concord, Tweed Heads, Woodville South, Fitzroy, Melbourne, Wendouree
2021-12-16
Active, closed
Clene Nanomedicine
Phase 2
40
Concord, Randwick
2021-11-13
Recruiting
University of Sydney
Phase 3
445
Bankstown, Camperdown, Concord, Frenchs Forest, Liverpool, New Lambton Heights, Randwick, Wollongong
2021-10-14
Recruiting
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
NCT05006716B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma
DrugTacabrutideg
BeOne Medicines
Phase 1/2
689
Concord, Waratah, Woolloongabba, Fitzroy, Heidelberg, Melbourne, Nedlands, West Perth
2021-09-13
Recruiting
University of Sydney
Phase 3
350
Concord, Kogarah, Liverpool, New Lambton Heights, Westmead, Birtinya, Brisbane, Bundaberg
2021-08-26
Active, closed
Inventiva Pharma
Phase 3
1,000
Concord, Liverpool, Penrith, Greenslopes, Herston, Box Hill, Clayton, Heidelberg
2021-08-19
By invitation
Viatris Innovation GmbH
Phase 3
25,000
Adelaide, Ballarat, Chermside, Clayton, Concord, Epping, Garran, Gosford
2021-08-14
Recruiting
A Study of BGB-11417 in Participants With Myeloid Malignancies
NCT04771130Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm
DrugsPosaconazole·Sonrotoclax·Azacitidine
BeOne Medicines
Phase 1/2
260
Concord, Kogarah, Orange, Southport, Clayton, Fitzroy, Heidelberg, Melbourne
2021-05-24
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
Bendigo, Concord, Fitzroy, Gosford, Kurralta Park, Melbourne, St Albans, Sydney
2021-03-18
Active, closed
Genmab
Phase 3
483
Bedford Park, Concord, Frankston, South Brisbane, Waratah, Westmead
2021-01-13
Recruiting
Nordic Lymphoma Group
Phase 3
300
Albury, Camperdown, Coffs Harbour, Concord, Cudgen, Garran, Hobart, Liverpool
2020-08-19
Active, closed
Eli Lilly and Company
Phase 3
996
Concord, Sydney, Brisbane, Maroochydore, Adelaide, Parkville, Murdoch
2020-06-22
Active, closed
AstraZeneca
Phase 3
818
Adelaide, Ballarat, Birtinya, Box Hill, Concord, Kurralta Park, North Sydney, Orange
2020-04-16
Active, closed
BeOne Medicines
Phase 1
437
Concord, Orange, Benowa, Tugun, Adelaide, Bedford PK, Box Hill, Clayton
2020-03-24
Active, closed
BeOne Medicines
Phase 3
955
Canberra, Concord, East Albury, Kogarah, St Leonards, Waratah, Westmead, Auchenflower
2020-01-16
Active, closed
BeOne Medicines
Phase 3
510
Garran, Concord, Cudgen, Darlinghurst, Gosford, Waratah, Birtinya, South Brisbane
2019-08-20
Recruiting
Population Health Research Institute
Phase 4
2,270
Garran, Bankstown, Camperdown, Concord, Liverpool, Newcastle, Westmead, Birtinya
2019-06-14
Active, closed
Corvus Pharmaceuticals, Inc.
Phase 1
151
Concord, Liverpool, Adelaide, Melbourne
2019-05-03
Active, closed
Celgene
Phase 3
363
Albury, Blacktown, Concord, Kogarah, Nowra, Waratah, Wollongong, Auchenflower
2019-01-02
Active, closed
First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
NCT03625037DLBCL, High-grade B-cell Lymphoma (HGBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), FL
DrugEpcoritamab
Genmab
Phase 1/2
666
Clayton, Concord, Fitzroy, Herston, Hobart, Kogarah, Malvern, Nedlands
2018-06-26
Active, closed
Bristol-Myers Squibb
Phase 3
545
Blacktown, Camperdown, Concord, Herston, Adelaide, Heidelberg, Nedlands
2018-04-18
Active, closed
Janssen Research & Development, LLC
Phase 2/3
1,409
Adelaide, Clayton, Concord, Heidelberg, Nedlands, North Terrace, Parkville, Penrith
2018-04-13
Active, closed
AbbVie
Phase 3
747
Concord, North Mackay, South Brisbane, Adelaide, Box Hill, Murdoch
2018-03-21
Active, closed
BeiGene
Phase 3
590
Concord, Cudgen, Waratah, Westmead, Auchenflower, Brisbane, Herston, Adelaide
2017-10-31
Active, closed
AbbVie
Phase 2
66
Concord, Kogarah, Clayton
2017-10-12
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
Concord, Adelaide
2017-07-26
Active, closed
Acerta Pharma BV
Phase 3
635
Bedford Park, Concord, Frankston, Gosford, Heidelberg, Herston, Kogarah, Murdoch
2017-04-05
Active, closed
Canadian Cancer Trials Group
Phase 2
301
Campbelltown, Coffs Harbour, Concord, Kingswood, Kogarah, Lismore, Liverpool, Randwick
2017-03-28
Active, closed
The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye.
NCT01320345Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies
DrugFenofibrate
University of Sydney
Phase 3
412
Garran, Camperdown, Concord, Darlinghurst, Liverpool, Merewether, Randwick, Saint Leonards
2016-11-03
Recruiting
UMC Utrecht
Phase 3
20,000
Canberra, Bankstown, Blacktown, Campbelltown, Caringbah, Concord, Dubbo, Frenchs Forest
2016-04-11
Active, closed
AstraZeneca
Phase 3
1,837
Adelaide, Auchenflower, Concord, Douglas, Gosford, Hobart, Malvern, Melbourne
2014-04-22
Active, closed
University of Sydney
Phase 3
1,125
Camperdown, Coffs Harbour, Concord, Darlinghurst, Kingswood, Kogarah, Orange, Port Macquarie
2014-03
Active, closed
A Long-term Extension Study of PCI-32765 (Ibrutinib)
NCT01804686Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
DrugIbrutinib
Janssen Research & Development, LLC
Phase 3
539
Adelaide, Coburg, Concord, Heidelberg, Melbourne, Perth, Prahran, Wahroonga
2013-09-09
Active, closed
AbbVie
Observational
8,250
Garran, Camperdown, Concord, East Lismore, New Lambton, Herston, South Brisbane, Adelaide
2013-04-29
Active, closed
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
NCT00310180Breast Adenocarcinoma, Hormone Receptor Positive, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7
DrugsTamoxifen Citrate·Tamoxifen·Exemestane·Anastrozole
National Cancer Institute (NCI)
Phase 3
10,273
Albury, Coffs Harbour, Concord, Lismore, Merewether, Newcastle, Waratah, Herston
2006-04-07
Rows per page Showing 1–124 of 124
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Australian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 15 October 2026. https://priyalifescience.com/clinical-trials-australia/city/concord

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Australia and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 3,343 studies in total at the last sync on 15 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 124 of those studies with a site in Concord.

How many clinical trials are recruiting in Concord?

67 of the 124 studies on this page are recruiting new participants as of the 15 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 54 are active but closed to new participants, and 3 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Concord), 124 studies
PhaseStudiesRecruitingShare
Phase 3693355.6%
Phase 220916.1%
Phase 11279.7%
Phase 1/21198.9%
Phase 2/3534%
Phase 4443.2%
Not applicable221.6%
Observational100.8%

Most active sponsors

Lead sponsors with the most studies (Concord)
Lead sponsorStudiesRecruiting
BeOne Medicines137
Janssen Research & Development, LLC104
Boehringer Ingelheim76
AstraZeneca64
AbbVie50
Takeda44
University of Sydney42
Amgen32
Hoffmann-La Roche32
Bayer22
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.